EBAC-accredited symposium at COMy 2023

Welcome to this EBAC-accredited symposium from The 9th World Congress on Controversies in Multiple Myeloma (COMy 2023).

Test your knowledge of multiple myeloma in our short quiz below before watching Professor Philippe Moreau, Dr Hira Mian and Dr Paul Richardson discuss the management of relapsed and refractory multiple myeloma (RRMM) in older and frail adults. 

To gain 1 CME credit, watch the entire session and complete the final knowledge assessment and evaluation form. You will need to achieve a score of 4/6 on the knowledge assessment to receive your CME credit.

Case study questions - when the case studies present in the symposium video answer the questions below.

Learning Objectives

After participating in this educational activity, you will be able to:

• Describe the need for communicating real-world clinical expertise in managing MM in older and/or frail patients who are not adequately represented in clinical trials
• Identify factors that should be considered when selecting a treatment for older and/or frail patients with MM
• State when frailty should be measured
• Recall data for emerging therapies for RRMM

Target Audience

This activity has been designed to meet the educational needs of haematologists, haemato-oncologists and healthcare professionals in contact with patients with multiple myeloma.

Faculty

Philippe Moreau, MD

Professor Philippe Moreau, MD, serves as Professor of Clinical Hematology and head of the translational research program in haematology and oncology at the University Hospital of Nantes, France. Professor Moreau’s clinical interests are focused on multiple myeloma and its treatment with high-dose therapy and novel agents.

Since 2020, Professor Moreau has been the chairman of the Intergroupe Francophone du Myélome (IFM). He has held the position of vice-president of the International Myeloma Society (IMS) since 2019, and he has been a member of the steering committee of the International Myeloma Working Group (IMWG) since 2013. He has served as the principal investigator of several international clinical trials evaluating carfilzomib, ixazomib, venetoclax, daratumumab, isatuximab and teclistamab. He was a member of the organising committee for the 2011 International Myeloma Workshop in Paris.

Professor Moreau’s research is widely published, with more than 600 peer-reviewed articles and reviews in high impact factor journals (94 as first or senior author in journals with an impact factor >6), including New England Journal of Medicine, The Lancet, Journal of Clinical Oncology, Lancet Oncology, and Blood. He is a frequently invited speaker at international haematological oncology meetings, and at educational sessions on multiple myeloma at ASH, ASCO and EHA. 

Professor Moreau received the Robert A. Kyle lifetime achievement award in 2018.

Hira Mian, MD

Dr Hira Mian is a haematologist at the Juravinski Cancer Centre and an Assistant Professor in the department of oncology at McMaster University in Hamilton, Canada, where she leads the Multiple Myeloma Program. Her research interests include optimising the care of older adults with multiple myeloma. She is the recipient of numerous local and national grants and an early career research award. She is also a board member of Myeloma Canada and an investigator with the Canadian Myeloma Research Group (CMRG) and the Canadian Cancer Clinical Trials Group.

Paul G. Richardson, MD

Dr Paul G. Richardson is the clinical program leader and director of research at the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute. Dr Richardson has spearheaded the development of several first-generation drugs for the treatment of multiple myeloma and has served as senior investigator for a number of trials. His work has focused on next-generation novel drugs, including panobinostat, and second-generation proteasome inhibitors, including ixazomib. More recently, his clinical innovations have been in the development of the breakthrough monoclonal antibodies elotuzumab and daratumumab, isatuximab and, more broadly, antibody–drug conjugates, including belantamab mafodotin. He has also contributed to the development of melflufen and selinexor, and has been an investigator in first-in-human studies of potent cereblon E3 ligase modulators (CELMoDs) for the treatment of RRMM, including mezigdomide. Over the past decade, Dr Richardson’s major effort has been focused on the development of lenalidomide, bortezomib and dexamethasone (RVd) for the treatment of newly diagnosed multiple myeloma.

Dr Richardson has published extensively, having authored or co-authored over 460 original articles and 340 reviews, chapters and editorials in peer-reviewed journals. In addition to holding positions on the editorial boards of leading journals, including the British Journal of Haematology and Haematologica, Dr Richardson has held numerous committee positions, including a 10-year tenure as Chair of the Alliance Myeloma Committee. He has been the recipient of a range of accolades in recognition of international contributions to multiple myeloma and stem cell transplantation; this includes the IMF Robert A. Kyle Lifetime Achievement Award in 2017 and the inaugural James Griffin Research Team Award (DFCI) for outstanding translational clinical research in multiple myeloma in 2023.

Disclosures

Hira Mian - Advisory board or panel fees from AbbVie Pharmaceuticals, Amgen, Bristol Myers Squibb, Janssen Pharmaceuticals, Pfizer, Sanofi and Takeda Pharmaceuticals, all relationships terminated. Grants or research support from Janssen Pharmaceuticals 

Philippe Moreau - Advisory board or panel fees from Abbvie Pharmaceuticals, Amgen, Celgene, GSK, Janssen Pharmaceuticals, Pfizer, Sanofi, Takeda Pharmaceuticals, all relationships terminated. Grants/research support from Abbvie Pharmaceuticals, Amgen, Celgene, GSK, Janssen Pharmaceuticals, Pfizer, Sanofi, Takeda Pharmaceuticals, all relationships terminated. 

Paul Richardson - Consultancy fees from AstraZeneca, Bristol-Myers Squibb/Celgene, GSK, Karyopharm, Oncopeptides, Sanofi and Takeda Pharmaceuticals. Grants/Research support from Bristol-Myers Squibb/Celgene, Karyopharm, Oncopeptides and Takeda Pharmaceuticals. 

In compliance with EBAC guidelines, all speakers/ chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.

References

1. Bird SA, Boyd K. Multiple myeloma: an overview of management. Palliative care and social practice. 2019;13:1178224219868235.
2. Podar K, Leleu X. Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers. 2021;13(20):5154.